MX9302300A - Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos. - Google Patents

Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos.

Info

Publication number
MX9302300A
MX9302300A MX9302300A MX9302300A MX9302300A MX 9302300 A MX9302300 A MX 9302300A MX 9302300 A MX9302300 A MX 9302300A MX 9302300 A MX9302300 A MX 9302300A MX 9302300 A MX9302300 A MX 9302300A
Authority
MX
Mexico
Prior art keywords
substituted alkyl
treatment
prostatic hypertrophy
alkyl
preparation
Prior art date
Application number
MX9302300A
Other languages
English (en)
Inventor
Miroyoshi Horikoshi
Takakazu Hamada
Koichi Kojima
Hitoshi Kurata
Koki Ishibashi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of MX9302300A publication Critical patent/MX9302300A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

Se ha descubierto ahora una serie de nuevos derivados de androstano que tiene actividad inhibidora de 5(alfa)reductasa valiosa, que es substancialmente mayor (en las pruebas de la presente por un orden de magnitud) que el mejor de la técnica anterior, es decir, el compuesto t-butílico, compuesto B.
MX9302300A 1992-04-20 1993-04-20 Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos. MX9302300A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9981692 1992-04-20
JP32804392 1992-12-08

Publications (1)

Publication Number Publication Date
MX9302300A true MX9302300A (es) 1994-03-31

Family

ID=26440917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302300A MX9302300A (es) 1992-04-20 1993-04-20 Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos.

Country Status (25)

Country Link
US (3) US5536714A (es)
EP (2) EP0567271B1 (es)
JP (1) JP2514778B2 (es)
KR (1) KR0146680B1 (es)
CN (2) CN1041095C (es)
AT (1) ATE154937T1 (es)
AU (1) AU656852B2 (es)
CA (1) CA2094300C (es)
CZ (2) CZ284206B6 (es)
DE (1) DE69311837T2 (es)
DK (1) DK0567271T3 (es)
ES (1) ES2105108T3 (es)
FI (1) FI931765A (es)
GR (1) GR3024896T3 (es)
HK (1) HK1000303A1 (es)
HU (1) HU219579B (es)
ID (1) ID18576A (es)
IL (1) IL105478A (es)
MX (1) MX9302300A (es)
NO (1) NO304891B1 (es)
NZ (1) NZ247449A (es)
PH (1) PH31052A (es)
RU (2) RU2114861C1 (es)
TW (2) TW238312B (es)
ZA (1) ZA932732B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1259419B (it) * 1991-05-24 1996-03-18 Erba Carlo Spa Steroidi 3-carbossi 17b - sostituiti insaturi utili come inibitori della testosterone 5 a reduttasi
RU94045872A (ru) * 1992-04-30 1996-08-27 Смитклайн Бичам Корпорейшн (US) 17 альфа - и 17 бета - замещенная эстра-1,3,5(10)-триен-3-карбоновая кислота, способ получения, промежуточные продукты, фармацевтическая композиция, способ ингибирования стероидной активности 2-редуктазы, способ снижения или поддержания размера предстательной железы, способы лечения
US5683995A (en) * 1992-11-18 1997-11-04 Smithkline Beecham Corporation 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors
GB9224148D0 (en) * 1992-11-18 1993-01-06 Smithkline Beecham Corp Compounds
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
WO1995006461A1 (en) * 1993-09-03 1995-03-09 Smithkline Beecham Corporation Stabilized tablet formulation
GB9324371D0 (en) * 1993-11-26 1994-01-12 Erba Carlo Spa Side chain fluoro substituted 3-carboxysteroids
GB9411103D0 (en) * 1994-06-03 1994-07-27 Smithkline Beecham Corp Compounds
GB9415183D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 3-carboxysteroids with a fluorinated side-chain
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
WO1999061055A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
EP1434786A4 (en) * 2001-10-03 2009-03-25 Merck & Co Inc ANDROSTAN-17-BETA-CARBOXAMIDE AS MODULATORS OF THE ANDROGEN RECEPTOR
AU2002361861A1 (en) * 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
WO2004097002A2 (en) * 2003-04-29 2004-11-11 The Miriam Hospital SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF
EP2392258B1 (en) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-informatics system
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
US7604386B2 (en) * 2005-11-18 2009-10-20 Federal-Mogul World Wide, Inc Lamp assembly having a socket made from high temperature plastic
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
IL295075A (en) 2009-05-06 2022-09-01 Laboratory Skin Care Inc Preparations for administration through the skin that include complexes of an active substance with calcium phosphate and methods of using them
WO2011004242A2 (en) * 2009-07-09 2011-01-13 Aurobindo Pharma Limited An improved process for the preparation of dutasteride
CN111362999B (zh) * 2020-03-16 2022-03-29 江苏联环药业股份有限公司 一种爱普列特杂质及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
AU1893492A (en) * 1991-04-17 1992-11-17 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5196411A (en) * 1991-08-16 1993-03-23 Merck & Co., Inc. 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors

Also Published As

Publication number Publication date
ID18576A (id) 1998-04-23
ATE154937T1 (de) 1997-07-15
RU2097387C1 (ru) 1997-11-27
DK0567271T3 (da) 1998-02-16
PH31052A (en) 1998-02-03
EP0567271B1 (en) 1997-07-02
CZ67893A3 (en) 1994-01-19
ZA932732B (en) 1993-10-28
NO931401D0 (no) 1993-04-16
JPH06279487A (ja) 1994-10-04
CZ90097A3 (cs) 1998-07-15
HK1000303A1 (en) 1998-02-20
ES2105108T3 (es) 1997-10-16
NO304891B1 (no) 1999-03-01
CA2094300A1 (en) 1993-10-21
CN1195666A (zh) 1998-10-14
US5717088A (en) 1998-02-10
NO931401L (no) 1993-10-21
IL105478A (en) 1998-03-10
CN1083070A (zh) 1994-03-02
RU95101838A (ru) 1997-01-10
EP0725074A2 (en) 1996-08-07
HU219579B (hu) 2001-05-28
TW238312B (es) 1995-01-11
GR3024896T3 (en) 1998-01-30
FI931765A (fi) 1993-10-21
CN1041095C (zh) 1998-12-09
KR930021654A (ko) 1993-11-22
EP0567271A2 (en) 1993-10-27
CA2094300C (en) 2003-01-28
AU656852B2 (en) 1995-02-16
CZ283791B6 (cs) 1998-06-17
CZ284206B6 (cs) 1998-09-16
HU9301155D0 (en) 1993-07-28
IL105478A0 (en) 1993-08-18
HUT64558A (en) 1994-01-28
EP0567271A3 (en) 1994-11-23
JP2514778B2 (ja) 1996-07-10
KR0146680B1 (ko) 1998-08-01
AU3698493A (en) 1993-10-21
DE69311837D1 (de) 1997-08-07
FI931765A0 (fi) 1993-04-19
US5536714A (en) 1996-07-16
NZ247449A (en) 1995-02-24
RU2114861C1 (ru) 1998-07-10
US5760025A (en) 1998-06-02
TW401420B (en) 2000-08-11
DE69311837T2 (de) 1998-02-12
EP0725074A3 (en) 1996-11-20

Similar Documents

Publication Publication Date Title
MX9302300A (es) Derivados esteroides para el tratamiento de hipertrofia prostatica, su preparacion y sus usos.
ATE139783T1 (de) Azasteroide zur behandlung prostatischer hypertrophie, ihre herstellung und verwendung
DK0620215T3 (da) 1H-indol-3-acetamidderivater som sPLA2-inhibitorer
ATE67503T1 (de) 17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
EP1175208A4 (en) COMPOSITION FOR PREVENTION OR TREATMENT OF DEMENTIA CONTAINING A HYDROXYCINNAMIC ACID DERIVATIVE OR AN EXTRACT OF AN ANGELICAE SPECIES CONTAINING SAID ACID
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
MX9800705A (es) Compuestos heterociclicos, composiciones para tratar isquemia de miocardio que los contiene, y procedimiento para su preparacion.
AU6101890A (en) Therapeutic agents for the treatment of peptic ulcer disease
DE69308406D1 (de) Thiadiazol-Derivate zur Behandlung von depressiven Zuständen